Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:44:27 ON 25 OCT 2007

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:44:37 ON 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 OCT 2007  HIGHEST RN 951288-30-5
DICTIONARY FILE UPDATES:  23 OCT 2007  HIGHEST RN 951288-30-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10584481.str
```





chain nodes :
13 14 15 16 17 18 19 27 30 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 21 22 23 24 25 26
chain bonds :
6-13 9-14 12-15 13-14 15-16 16-17 16-30 16-31 17-18 17-19 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 21-22
21-26 22-23 23-24 24-25 25-26
exact/norm bonds :
9-14 16-30 16-31 17-18 17-19
exact bonds :
6-13 12-15 13-14 15-16 16-17 26-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 21-22
21-26 22-23 23-24 24-25 25-26
isolated ring systems :
containing 1 : 7 : 21 :

G1:O,N

G2:H,O,X

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom
27:CLASS 28:Atom 30:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 14:45:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2369 TO ITERATE

84.4% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44461 TO 50299
PROJECTED ANSWERS: 2 TO 139

L2 2 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 14:45:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 47401 TO ITERATE

100.0% PROCESSED 47401 ITERATIONS 18 ANSWERS
SEARCH TIME: 00.00.01

L3 18 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 14:45:18 ON 25 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Oct 2007 VOL 147 ISS 18
FILE LAST UPDATED: 24 Oct 2007 (20071024/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=>
Uploading C:\Program Files\Stnexp\Queries\105844811.str





chain nodes :
13 14 15 16 17 18 19 28 29 33 34 35 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 21 22 23 24 25 26
chain bonds :
6-13 9-14 12-15 13-14 15-16 16-17 16-28 16-29 17-18 17-19 26-38 33-34 33-38 34-35
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 21-22 21-26 22-23 23-24 24-25 25-26

exact/norm bonds :
9-14 16-28 16-29 17-18 17-19 33-34 33-38
exact bonds :
6-13 12-15 13-14 15-16 16-17 26-38 34-35
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 21-22
21-26 22-23 23-24 24-25 25-26
isolated ring systems :
containing 1 : 7 : 21 :

G1:O,N

G2:H,O,X

G3:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom
28:CLASS 29:CLASS 33:CLASS 34:CLASS 35:CLASS 38:CLASS 41:Atom

L5 STRUCTURE UPLOADED

=> s l5
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 14:55:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2789 TO ITERATE

71.7% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 52613 TO 58947
PROJECTED ANSWERS: 1 TO 97

L6 1 SEA SSS SAM L5

L7 1 L6

=> dup rem l7 l4
PROCESSING COMPLETED FOR L7
PROCESSING COMPLETED FOR L4
L8 3 DUP REM L7 L4 (1 DUPLICATE REMOVED)

=> d l8 ibib abs hitstr hitind 1-3

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2004:412803 CAPLUS
DOCUMENT NUMBER: 141:1264
TITLE: Receptor function controlling agent
INVENTOR(S): Fukatsu, Kohji; Sasaki, Shinobu; Hinuma, Shuji; Ito,
Yasuaki; Suzuki, Nobuhiro; Harada, Masataka; Yasuma,
Tsuneo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 442 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

#4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041266	A1	20040521	WO 2003-JP14139	20031106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2505322	A1	20040521	CA 2003-2505322	20031106
AU 2003277576	A1	20040607	AU 2003-277576	20031106
JP 2005015461	A	20050120	JP 2003-376833	20031106
EP 1559422	A1	20050803	EP 2003-810621	20031106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1735408	A	20060215	CN 2003-80108260	20031106
PRIORITY APPLN. INFO.:			JP 2002-324632 A	20021108
			JP 2003-16889 A	20030127

JP 2003-153986 A 20030530

WO 2003-JP14139 W 20031106

OTHER SOURCE(S): MARPAT 141:1264

AB A GPR40 receptor function controlling agent which contains a compound having an aromatic ring and a group capable of releasing a cation and is useful as a insulin secretion promoting agent or a preventive/remedy for diabetes, etc.

IT 691903-50-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(GPR40 receptor function controlling agents as antidiabetics)

RN 691903-50-1 CAPLUS

CN Benzenepropanoic acid, 4-[[4-[(pentylphenylamino)methyl]phenyl]methoxy]- (CA INDEX NAME)



IC ICM A61K031-192
ICS A61K031-195; A61K031-216; A61K031-343; A61K031-381; A61K031-401; A61K031-404; A61K031-426; A61K031-428; A61K031-437; A61P001-04; A61P003-04; A61P003-06; A61P003-10; A61P007-02; A61P007-10; A61P009-10; A61P009-12; A61P013-12; A61P015-08

CC 1-10 (Pharmacology)
Section cross-reference(s): 28, 63

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(GPR40 receptor function controlling agents as antidiabetics)

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:633643 CAPLUS

DOCUMENT NUMBER: 139:180343

TITLE: Preparation of aromatic amino acid derivatives as anticancer agents

INVENTOR(S): Endo, Hitoshi; Kanai, Yoshikatsu; Tsujihara, Kenji; Saito, Kunio

PATENT ASSIGNEE(S): Japan

SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066574	A1	20030814	WO 2003-JP1081	20030203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2475434	A1	20030814	CA 2003-2475434	20030203
AU 2003208105	A1	20030902	AU 2003-208105	20030203
EP 1481965	A1	20041201	EP 2003-703151	20030203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1630632	A	20050622	CN 2003-803549	20030203
US 2005119256	A1	20050602	US 2005-503125	20050209
PRIORITY APPLN. INFO.:			JP 2002-31216 A	20020207
			WO 2003-JP1081 W	20030203

OTHER SOURCE(S): MARPAT 139:180343
GI



I

AB Aromatic amino acid derivs. represented by the following general formula (I)
or pharmacol. acceptable salts thereof [wherein R1 represents hydrogen or
an amino-protecting group; R2 represents hydrogen, alkylaralkyl or aryl;
R3 represents (1) halogeno, (2) aroylamino, (3) Ph substituted by lower alkyl, Ph, phenoxy, etc., (4) naphthyl or tetrahydronaphthyl optionally substituted by hydroxy, lower alkoxy or di(lower alkyl)amino, (5) an N-,

O- and/or S-containing unsatd. monocyclic heterocycle group substituted by lower alkyl, Ph, naphthyl or tetrahydroquinolyl, or (6) an N-, O- and/or S-containing fused heterocycle group, which may be unsatd. or partly saturated, optionally substituted by oxo, carboxy, amino, lower alkyl, etc.; X represents halogeno, alkyl or alkoxy; Y represents oxygen or nitrogen; p is 0 or 1; m is 0, 1 or 2; and n is an integer of from 0 to 5] are prepared These compds. inhibit a transporter (LAT1) of essential amino acids which are one of the main nutrients for cancer cells and induce depletion of the essential amino acids in the cancer cells, thereby inhibit the proliferation of the cancer cells. Thus, 0.2 mL pyridine was added to a suspension of N-trifluoroacetyl-3-hydroxy-L-phenylalanine Et ester 159, 2-naphthaleneboronic acid 186, mol. sieve 4A 204, and Cu(OAc)2 153 mg in 7 mL CH2Cl2, stirred at room temperature for 16 h in air to give, after workup and silica gel chromatog., 89% N-trifluoroacetyl-3-(2-naphthyloxy)-L-phenylalanine Et ester (II). 0.5 N aqueous NaOH was added to a solution of II (94 mg) in 2 mL THF at 5°, stirred at 5° for 69 h, acidified with 1 N aqueous HCl to pH 3-4, and filtered to give 78% 3-(2-naphthyloxy)-L-phenylalanine (III). In an assay for a LAT1 inhibitory activity, III and 3-[3-(6-dimethylaminopyridyl)phenoxy]-L-phenylalanine in vitro showed IC50 of 0.1 and 0.01 μg/mL, resp., for inhibiting the uptake of [14C]-L-tyrosine by human prostatic cancer T24 cells.

IT 579524-19-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic amino acid derivs. as anticancer agents for inhibiting proliferation of cancer cells by inhibiting essential amino acid transporter (LAT1))

RN 579524-19-9 CAPLUS
CN L-Tyrosine, 3,5-dichloro-O-[[2-(phenylmethyl)phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 579526-20-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of aromatic amino acid derivs. as anticancer agents for inhibiting
proliferation of cancer cells by inhibiting essential amino acid transporter (LAT1))
RN 579526-20-8 CAPLUS
CN L-Tyrosine, 3,5-dichloro-O-[[2-(phenylmethyl)phenyl]methyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C07C229-36
ICS C07C255-54; C07D207-333; C07D209-08; C07D213-30; C07D213-74; C07D215-20; C07D263-32; C07D263-56; C07D277-24; C07D307-80; C07D307-91; C07D311-30; C07D317-64; C07D401-04; C07D413-04; C07D417-04; C07D471-04; A61K031-198; A61K031-277
CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1

(prepn. of arom. amino acid derivs. as anticancer agents for inhibiting
proliferation of cancer cells by inhibiting essential amino acid transporter (LAT1))
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:154382 CAPLUS
DOCUMENT NUMBER: 138:187795
TITLE: Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors
INVENTOR(S): Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1009 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003016254	A1	20030227	WO 2002-JP8120		20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2457468	A1	20030227	CA 2002-2457468		20020808
AU 2002323916	A1	20030303	AU 2002-323916		20020808
EP 1431267	A1	20040623	EP 2002-755874		20020808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002011810	A	20040824	BR 2002-11810		20020808
CN 1551866	A	20041201	CN 2002-817376		20020808
HU 2004001963	A2	20050128	HU 2004-1963		20020808
NZ 531153	A	20051028	NZ 2002-531153		20020808
NZ 541950	A	20070223	NZ 2002-541950		20020808
ZA 2004000973	A	20050104	ZA 2004-973		20040205
NO 2004000564	A	20040510	NO 2004-564		20040206
MX 2004PA01253	A	20040603	MX 2004-PA1253		20040209
US 2006258728	A1	20061116	US 2004-486220		20040909
PRIORITY APPLN. INFO.:			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808

OTHER SOURCE(S): MARPAT 138:187795
GI



I

AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricarbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepared These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisoindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide , (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)p ropenamide, (thiophenylmethylphenyl)propenamide,

(pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propana
mide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide,
(phenoxymethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-
one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to
PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having
antagonism, the compds. I are useful in preventing and/or treating
diseases such as pain, allodynia, hyperalgesia, pruritus (itching),
urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer
tree) dermatitis, allergic conjunctivitis, symptoms during dialysis,
asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis,
pollakiuria (increased urinary frequency), urination disorder, ejaculation
(semination) disorder, fever (pyrexia), systemic inflammation reaction,
learning disorder, Alzheimer's disease, neovascularization, cancer
formation, cancer proliferation, cancer metastasis to organs, cancer
metastasis to bone, hypercalcemia accompanied by cancer metastasis to
bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat
burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic
nephritis, blood electrolyte disorder, imminent abortion, threatened
abortion, excessive menstruation, dysmenorrhea, endometriosis,
premenstrual syndrome, uterine gland myopathy, reproduction disorder, and
stress. They are also useful in preventing and/or treating anxiety,
depression, psychophysiol. disorder, mental retardation, thrombus,
embolism, transient ischemic attack, cerebral infarction, atheroma, organ
transplant, heart failure, hypertension, myocardial infarction,
arteriosclerosis, circulation disorders or ulcers associated therewith, nerve
disorders, vascular dementia, edema, diarrhea, constipation, biliary
excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel
syndrome, reduction of rebound after using steroid drugs, aids for decreasing
or removing steroid drugs, bone diseases, systemic granuloma, immune
diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell
death, lung disorder, liver disorder, acute hepatitis, myocardial
ischemia, Kawasaki disease, multiple organ failure, chronic headache,
angiitis, venous failure, varicose vein (varicosis), anal fistula,
diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis.
Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester
was mesylated by methanesulfonyl chloride in the presence of Et3N in THF

at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, Ep2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation containing (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

IT 499155-37-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

RN 499155-37-2 CAPLUS
CN Benzenepropanoic acid, 2-[[[1-(3,5-dimethylphenyl)-3-methylbutyl]amino]carbonyl]-4-[[2-(phenylmethyl)phenyl]methoxy]- (CA INDEX NAME)



IC ICM C07C057-40
ICS C07C057-44; C07C069-736; C07C229-34; C07C233-47; C07C233-55; C07C233-65; C07C233-81; C07C233-87; C07C235-38; C07C235-42; C07C235-46; C07C235-48; C07C235-54; C07C235-56; C07C237-30; C07C239-18; C07C255-37; C07C255-55; C07C255-57

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 25, 27, 63

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.77	198.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

STN INTERNATIONAL LOGOFF AT 14:56:54 ON 25 OCT 2007